A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

~26 mi. (Warszewo, Poland, +144 more cities)

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 2405), +1 more facility

Clear Cell Renal Cell Carcinoma

belzutifan, +3 more drugs

immunotherapy, +1 more type

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

~26 mi. (Warszewo, Poland, +176 more cities)

Szpital Kliniczny im Ks Anny Mazowieckiej ( Site 2481)

Endometrial Carcinoma, +1 more condition

chemotherapy, +2 more drugs

chemotherapy, +2 more types

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

~26 mi. (Warszewo, Poland, +93 more cities)

Narodowy Instytut Onkologii ( Site 1051)

Bladder Carcinoma, +1 more condition

cisplatin, +4 more drugs

chemotherapy, +3 more types

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

~26 mi. (Warszewo, Poland, +159 more cities)

Luxmed Onkologia sp. z o. o. ( Site 1051)

Superficial Bladder Urothelial Carcinoma

cisplatin, +2 more drugs

chemotherapy, +1 more type

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

~26 mi. (Warszewo, Poland, +163 more cities)

Luxmed Onkologia sp. z o. o. ( Site 1051)

Bladder Urothelial Carcinoma

cystectomy, +2 more drugs

chemotherapy, +3 more types

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

~26 mi. (Warszewo, Poland, +158 more cities)

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (

Non-Small Cell Lung Carcinoma

olaparib, +4 more drugs

chemotherapy, +3 more types

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

~26 mi. (Warszewo, Poland, +131 more cities)

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 1704)

HER2 Negative

Adenocarcinoma of the Gastroesophageal Junction, +2 more conditions

CAPOX regimen, +3 more drugs

chemotherapy, +2 more types

A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

~26 mi. (Warszewo, Poland, +93 more cities)

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 2400)

Clear Cell Renal Cell Carcinoma

belzutifan, +1 more drug

targeted therapy

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

~26 mi. (Warszewo, Poland, +150 more cities)

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (

Head and Neck Squamous Cell Carcinoma

cisplatin, +2 more drugs

chemotherapy, +2 more types

Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

~26 mi. (Warszewo, Poland, +137 more cities)

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 0951)

Skin Squamous Cell Carcinoma

pembrolizumab

immunotherapy

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010)

~26 mi. (Warszewo, Poland, +127 more cities)

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Glowy i Szyi ( Site

Hypopharyngeal Squamous Cell Carcinoma, +3 more conditions

lenvatinib, +1 more drug

immunotherapy, +1 more type

Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

~26 mi. (Warszewo, Poland, +67 more cities)

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (

Non-Squamous Non-Small Cell Lung Carcinoma, +1 more condition

carboplatin, +5 more drugs

chemotherapy, +1 more type